An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell Transplantation
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs ODN/Pam2 (Primary)
- Indications Pneumocystis pneumonia
- Focus Therapeutic Use
- Sponsors Pulmotect
- 08 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
- 08 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018.
- 08 Aug 2017 Planned initiation date changed from 1 Apr 2017 to 1 Sep 2017.